Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
23/07/2026 06:31
BRIEF-Sprint Bioscience Partners With Lilly Tunelab For Drug Development July 23 (Reuters) - Sprint Bioscience AB SPRINT.ST:
ANNOUNCES AGREEMENT WITH LILLY TUNELAB FOR AI-DRIVEN DRUG DEVELOPMENT
TO UTILIZE TUNELAB AI AND MACHINE LEARNING MODELS TO ACCELERATE PORTFOLIO DEVELOPMENT
GAINS ACCESS TO LILLY'S PREDICTIVE DRUG DEVELOPMENT MODELS VIA TUNELAB
Source text: ID:nMFN12skWY
Further company coverage: SPRINT.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Sprint Bioscience AB
See all newsBrief: Sprint Bioscience And Max IV Receive Funding From Vinnova
Brief: Sprint Bioscience Q2 Loss After Tax SEK 16.2 Million
Brief: Sprint Bioscience Announces Deal With Lilly Tunelab
Brief: Sprint Bioscience Partners With Lilly Tunelab For Drug Development
Brief: Sprint Bioscience Q1 Operating Loss SEK 14.3 Mln